---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015726"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:24:00.242310+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech Q3 net loss $15M; FDA approved Emrosi on Nov 4; cosibelimab PDUFA Dec 28

## Summary
- Net loss attributable to common stockholders $15.0M ($0.76/shr) vs $7.1M loss in Q3 2023.
- Consolidated net revenue $14.6M (all from dermatology products); Q3 2023 revenue $34.8M included $19M license fee.
- Cash and equivalents $58.9M as of Sep 30, 2024, down $22M YTD; included $25.6M at Fortress and private subs.
- Paused Series A preferred dividends in July 2024, deferring ~$0.7M cash/month; new $35M Oaktree loan terms.
- FDA approval of Emrosi on Nov 4; cosibelimab PDUFA date Dec 28; Checkpoint raised $9.2M in Nov warrant exercises.

## SEC filing metadata
- accession: 0001558370-24-015726
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/0001558370-24-015726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837024015726/fbio-20241114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015726
- JSON: https://secwatch.observer/filing/0001558370-24-015726.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.